<DOC>
	<DOCNO>NCT02900131</DOCNO>
	<brief_summary>Atopic Dermatitis chronic relapse eczematous skin disease increase prevalence . Complementary alternative medical approach employ relieve symptom Atopic Dermatitis . We aim establish basic clinical efficacy safety data Jaungo patient Atopic Dermatitis .</brief_summary>
	<brief_title>Efficacy , Safety Dose Finding Trial Topical Jaungo Application Atopic Dermatitis Patients</brief_title>
	<detailed_description>This study randomise , double blind , placebo-controlled , single-centre trial three parallel arm ( trial group 1 , trial group 2 , control group ) . The diagnosis Atopic Dermatitis make accord criterion Hanifin Rajka . Participants receive Jaungo placebo-drug three week . Participants trial group 1 apply Jaungo placebo lesion day three week . Participants trial group 2 apply Jaungo lesion twice day three week . Participants control group apply placebo lesion twice day three week . Each participant examine EASI ( Eczema area severity index ) , SCORAD ( SCORing Atopic Dermatitis ) , TEWL ( Transepidermal water loss ) DLQI ( Dermatology Life Quality Index ) apply medication . The outcomes evaluate maintenance safety Draize score , blood test expert 's opinion .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>1 . The diagnosis AD make accord criterion Hanifin Rajka 2 . Age : 5 year 65 year 3. objective SCORAD ≦40 , Diagnosis Mild Moderate Atopic Dermatitis ( AD ) 4 . Exoriation≥1 , Lichenification≥1 , Dryness≥1 Exoriation+Lichenification+Dryness≥3 5 . Participants able express intention 6 . Participants willing provide write informed consent 1 . Participants ooze lesion 2 . Users follow medication prior trial period ① Oral steroid , immunosuppressant antibiotic within 4 week prior trial ② Topical steroid , immunosuppressant antibiotic within 2 week prior trial ③ Light therapy within 2 week prior trial ④ Other medication think inappropriate researcher 3 . Participants severe burn wide wound 4 . Participants ooze ulcer lesion 5 . Allergic reaction Angelica gigas , Siebold et Zuccarini , sesame oil lard 6 . Participants skin disease except atopic dermatitis 7 . Participants severe renal function disease ( sCr &gt; 2.0 mg/dL ) 8 . Participants severe liver function disease ( ALT , AST , ALP ≥ 2.5 × normal limit ) 9 . Participants uncontrolled chronic disease 10 . Pregnancy , lactation 11 . Participation another clinical trial within one month enrolment 12 . Underlying disease history severe disease , abnormal state ( paralysis ; mental retardation emotional mental problem ; disease affect absorption drug ; enough time participate trial ; visual disturbance hearing impairment ; inability understand write consent engage study ) 13 . Judgment expert potential subject 's participation inappropriate .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>